Aclarion, Inc. (ACON) Stock Price Quote, News & Filings

Summary

Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.

Website

www.aclarion.com

Location

Broomfield, CO, US

Phone650-241-1741

Employees11

CEOBrent Ness

Sector

Health Care

Industry

Health Care Equipment & Supplies

IPO DateApr 22, 2022

Ask AI

Company overview

Business model, segments, and competition.

Peer comparison

Metrics vs closest competitors.

Guidance & outlook

Forward guidance and assumptions.

Bull vs bear case

Upside drivers and key risks.

Valuation snapshot

Multiples vs history and peers.

Competitive moat

Defensibility and market position.

Management track record

Leadership and capital allocation history.

How it makes money

A short diagram of the business model.

Latest Documents

Mentions in Filings

… 01. He is a graduate of Cornell University Medical College in New York City and earned a BS in electrical engineering management at the U. S. Military Academy in West Point, NY. Dr. Thramann currently serves as the Executive Chairman of Aclarion, Inc. (NASDAQ: ACON), a healthcare technology company that is leveraging MR Spectroscopy, biomarkers, and augmented intelligence algorithms to improve the diagnosis and treatment of chronic low back pain.
AUDDIA INC.Aclarion, Inc.·PRE 14A - PRELIMINARY NOTICE AND PROXY STATEMENT·Q4 26·12 Nov
… 01. He is a graduate of Cornell University Medical College in New York City and earned a BS in electrical engineering management at the U. S. Military Academy in West Point, NY. Dr. Thramann currently serves as the Executive Chairman of Aclarion, Inc. (NASDAQ: ACON), a healthcare technology company that is leveraging MR Spectroscopy, biomarkers, and augmented intelligence algorithms to improve the diagnosis and treatment of chronic low back pain.
AUDDIA INC.Aclarion, Inc.·DEFM14A - DEFINITIVE PROXY RELATING TO MERGER·Q3 26·11 Aug
… 01. He is a graduate of Cornell University Medical College in New York City and earned a BS in electrical engineering management at the U. S. Military Academy in West Point, NY. Dr. Thramann currently serves as the Executive Chairman of Aclarion, Inc. (NASDAQ: ACON), a healthcare technology company that is leveraging MR Spectroscopy, biomarkers, and augmented intelligence algorithms to improve the diagnosis and treatment of chronic low back pain.
McCarthy Finney, Inc.Aclarion, Inc.·424B3 - Prospectus filing (Rule 424(b)(3))·Q3 26·11 Aug
… 01. He is a graduate of Cornell University Medical College in New York City and earned a BS in electrical engineering management at the U. S. Military Academy in West Point, NY. Dr. Thramann currently serves as the Executive Chairman of Aclarion, Inc. (NASDAQ: ACON), a healthcare technology company that is leveraging MR Spectroscopy, biomarkers, and augmented intelligence algorithms to improve the diagnosis and treatment of chronic low back pain.
McCarthy Finney, Inc.Aclarion, Inc.·DEFM14A - DEFINITIVE PROXY RELATING TO MERGER·Q3 26·11 Aug
… 01. He is a graduate of Cornell University Medical College in New York City and earned a BS in electrical engineering management at the U. S. Military Academy in West Point, NY. Dr. Thramann currently serves as the Executive Chairman of Aclarion, Inc. (NASDAQ: ACON), a healthcare technology company that is leveraging MR Spectroscopy, biomarkers, and augmented intelligence algorithms to improve the diagnosis and treatment of chronic low back pain.
McCarthy Finney, Inc.Aclarion, Inc.·S-4/A - FORM S-4 AMENDMENT NO. 3·Q3 26·29 Jul
… 01. He is a graduate of Cornell University Medical College in New York City and earned a BS in electrical engineering management at the U. S. Military Academy in West Point, NY. Dr. Thramann currently serves as the Executive Chairman of Aclarion, Inc. (NASDAQ: ACON), a healthcare technology company that is leveraging MR Spectroscopy, biomarkers, and augmented intelligence algorithms to improve the diagnosis and treatment of chronic low back pain.
McCarthy Finney, Inc.Aclarion, Inc.·S-4 - Registration statement (business combination)·Q2 26·14 May

Key Stats

Trading

Px/Chg 1D$2.38 / -2.46%

Prev Close$2.35

% of 52Wk H20.28%

Avg Volume92.81K

Beta0.88

Mkt Cap1.27M

FD Mkt Cap1.30M

Float

Shrs Out/Float533.31K / 2.04M

Short Float0.10%

Days to Cover1.00

Stock Repurchased$0.00

Current Valuation

EV-17735700.58

EV/EBITDA2.27

EV/Sales-227.73

P/B0.06

P/S16.30

FCF Yield-208.14%

ROE-14.52%

ROA-13.83%

Current Ratio19.65

Estimates

P/E-0.16

Est P/E0.00

Est EPS-1.55

Est PEG0.00

Valuation

Metric	5Yr Avg	Jun '23	May '24	May '25	May '26	Oct '26
PRICE-BASED RATIOS
Price / Earnings	-0.38	-0.59	-0.00	-0.00	-0.89	-0.44
Price / Sales	43.84	69.39	0.21	0.15	90.69	58.78
Price / Book Value	0.41	1.88	-0.02	0.01	0.13	0.06
Price / Free Cash Flow	-0.46	-0.81	-0.00	-0.00	-1.00	-0.47
ENTERPRISE VALUE METRICS
Enterprise Value	-5.1	2.7	0.1	-0.4	-10.3	-17.8
Enterprise Value / Sales	-272.59	45.02	1.60	-9.77	-559.55	-840.23
Enterprise Value / EBITDA	2.31	-0.50	-0.03	0.07	5.66	6.36
Enterprise Value / EBIT	2.25	-0.49	-0.03	0.07	5.47	6.22

Financials

Full Financials

Millions USD	5Yr CAGR (%)	Dec '21	Dec '22	Dec '23	Dec '24	Dec '25
INCOME STATEMENT
Revenue	5.9%	0.1	0.1	0.1	0.0	0.1
Gross Income	123.2%	-0.0	-0.0	-0.0	-0.1	-0.2
EBITDA	13.1%	-4.3	-5.4	-4.1	-6.3	-7.0
EBIT	12.8%	-4.5	-5.6	-4.3	-6.5	-7.2
Net Income	9.9%	-5.0	-7.1	-4.9	-7.0	-7.2
EPS (Diluted)	-89.7%	-120,035.00	-177,396.00	-79,782.00	-7,480.22	-13.61
BALANCE SHEET
Cash & ST Inv	129.6%	0.4	1.5	1.0	0.5	12.0
Total Assets	64%	1.9	2.9	2.5	2.1	13.7
Total Liabilities	-42.4%	7.6	0.7	3.2	1.2	0.8
Total Shareholder Equity	—	-5.7	2.2	-0.7	1.0	12.8
CASH FLOW
Net Operating Cash Flow	32.1%	-2.3	-4.9	-3.6	-5.3	-7.2
Cap Ex	1,111.3%	-0.0	-0.2	-0.1	-0.3	-0.0
Free Cash Flow	32.2%	-2.3	-5.2	-3.8	-5.6	-7.2

Enterprise Value Bridge

Millions USD		13 Nov '26
Price (As of 13 Nov '26)		1.60
Basic Shares		0.53
Market Cap		0.9
Diluted Shares		2.78
Fully Diluted Shares Outstanding		2.78
Fully Diluted Market Cap		4.4
+Consolidated Debt		-
−In-the-Money Convertible Debt		—
+Capital Leases		-
+Operating Leases		—
−Cash & Equivalents		-14.2
−Short-term Investments		-
+Total Preferred		-
−In-the-Money Convertible Preferred		—
−Investments in Unconsolidated Subs		—
+Non-Controlling Interest		-
+Pension Liabilities		—
Enterprise Value		-13.3

Related companies